Montalis (Montelukast)

Montelukast, the active ingredient in Montalis, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in both adults and children, helping to reduce airway inflammation and improve breathing control.

GNH USA supplies Montalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks and regulatory compliance across EU and other markets. The company adheres to Good Distribution Practice, ensuring product integrity and timely delivery to healthcare providers worldwide.

Montelukast is indicated for conditions involving leukotriene‑mediated airway inflammation. - Asthma: improves control of persistent asthma, reduces frequency of exacerbations, and decreases need for rescue inhaler use. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity, allowing better exercise tolerance in susceptible individuals.

Montelukast may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate headache. - Upper respiratory tract infection: symptoms of cold or sinusitis. - Cough: occasional non‑productive cough. - Abdominal pain: mild stomach discomfort. - Diarrhea: loose stools. - Rash: mild skin redness or itching.

Serious or Rare Side Effects: - Neuropsychiatric events: agitation, anxiety, depression, or suicidal thoughts. - Allergic reactions: hives, swelling of face, lips or tongue. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Angioedema: rapid swelling of the face or airway. - Blood dyscrasias: eosinophilia or neutropenia.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Pregnancy: category B; use only if benefit outweighs potential risk. - Lactation: excreted in breast milk; weigh benefits against infant exposure. - Hepatic impairment: monitor liver function in patients with liver disease. - Concomitant asthma therapy: continue inhaled corticosteroids; do not substitute. - Neuropsychiatric monitoring: observe for mood changes or suicidal ideation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: induces metabolism leading to decreased effectiveness.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may increase risk of neuropsychiatric side effects. - Warfarin: potential alteration of anticoagulant effect; monitor INR. - CYP2C9 inhibitors (e.g., fluconazole): may modestly increase montelukast levels. - Herbal supplements (St. John’s wort): may induce metabolism, reducing drug exposure.